Filing Flows › Biodesix (BDSX) › Q1 2025
Biodesix (BDSX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Biodesix (BDSX) reported revenue of $18.0M for the first quarter 2025 (Q1 2025), +21% from a year earlier and -12% from the quarter before. Operating margin was -50.9%, net loss $11.1M (61.8% of revenue).
Biodesix, Q1 2025: revenue $18.0M (+21% year over year), operating margin -50.9%, net loss $11.1M, operating cash flow −$8.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.0M | -12% | +21% |
| Operating profit | −$9.1M | — | — |
| Net earnings | −$11.1M | — | — |
| Operating cash flow | −$8.6M | — | — |
What changed
Revenue was $18.0M in Q1 2025, up 21% year over year and down 12% from the previous quarter. Diagnostic Tests was the largest line at 91% of revenue. Diagnostic Tests added $2.5M year over year (up 18%), 80% of the total change.
Operating costs exceeded revenue by $9.1M, an operating margin of -50.9%. Total costs grew 5% against revenue growth of 21%. The fastest-growing cost line was Research & development (+41%). The quarter ended with a net loss of $11.1M, wider than the previous quarter's $8.3M loss.
Operating cash flow was −$8.6M. Non-cash charges added back $1.4M of depreciation and amortization and $1.0M of share-based compensation. Capital expenditures of $74K exceeded it, leaving free cash flow of −$8.7M.
Questions
What was Biodesix's revenue in the first quarter 2025?
Biodesix (BDSX) reported revenue of $18.0M for the first quarter 2025 (Q1 2025), +21% from a year earlier and -12% from the quarter before.
Was Biodesix profitable in the first quarter 2025?
Operating loss was $9.1M (-50.9% of revenue) and net loss $11.1M.
Source: Biodesix 10-Q on SEC EDGAR.